Nucleotide Synthesis
| Category | Mechanisms |
|---|---|
| Also known as | purine and pyrimidine biosynthesis |
| Last updated | 2026-04-14 |
| Reading time | 4 min read |
| Tags | mechanismmetabolism |
Overview
Nucleotide synthesis is the set of metabolic pathways that produce the building blocks of DNA, RNA, ATP, GTP, NAD, FAD, coenzyme A, and other essential cofactors. Nucleotides comprise a nitrogenous base (purine or pyrimidine), a pentose sugar (ribose or deoxyribose), and one or more phosphate groups. Cells acquire nucleotides by two complementary routes: de novo synthesis from simple precursors (amino acids, ribose-5-phosphate, carbon dioxide, ammonia), and salvage from preformed bases or nucleosides that arise from nucleic acid turnover or dietary intake.
De novo purine synthesis builds the purine ring on ribose-5-phosphate in ten enzymatic steps, using glycine, glutamine, aspartate, formate, and bicarbonate. De novo pyrimidine synthesis first constructs the pyrimidine ring (starting from carbamoyl phosphate and aspartate) and then attaches it to ribose-5-phosphate. Salvage pathways reuse purine and pyrimidine bases through phosphoribosyltransferases and nucleoside kinases; they are especially important in tissues with limited de novo capacity (brain, erythrocytes, mature leukocytes).
Nucleotide balance is critical: imbalances affect DNA replication fidelity, RNA integrity, and cellular proliferation. Many chemotherapeutics target nucleotide synthesis, and inborn errors of metabolism affecting the pathways produce disorders such as Lesch-Nyhan syndrome.
Mechanism / Process
-
PRPP synthesis. Ribose-5-phosphate from the pentose phosphate pathway is activated to phosphoribosyl pyrophosphate (PRPP) by PRPP synthetase.
-
De novo purine synthesis. Ten enzymatic steps build the purine ring on PRPP, starting with glutamine PRPP amidotransferase (the rate-limiting step, feedback-inhibited by AMP and GMP). The product is inosine monophosphate (IMP), which is converted to AMP or GMP by separate branches requiring aspartate or glutamine, respectively.
-
De novo pyrimidine synthesis. Carbamoyl phosphate synthetase II (cytosolic) produces carbamoyl phosphate from glutamine and bicarbonate. Aspartate transcarbamoylase condenses it with aspartate, and ring closure and oxidation by dihydroorotate dehydrogenase (a mitochondrial inner membrane enzyme) produces orotate. Orotate is joined to PRPP to yield OMP, decarboxylated to UMP, and phosphorylated to UDP and UTP. CTP is formed from UTP by CTP synthetase, which transfers an amide from glutamine.
-
Deoxyribonucleotide formation. Ribonucleotide reductase (RNR) reduces ribonucleoside diphosphates to deoxyribonucleoside diphosphates for DNA synthesis. RNR is exquisitely regulated by allosteric sites that balance the four dNTPs.
-
Thymidylate synthesis. dUMP is methylated to dTMP by thymidylate synthase, using methylenetetrahydrofolate as a methyl donor — a folate-dependent step critical for DNA synthesis.
-
Salvage pathways. HGPRT salvages hypoxanthine and guanine by attaching them to PRPP, producing IMP and GMP. APRT salvages adenine. Pyrimidine salvage uses uridine/cytidine kinases and thymidine kinase.
-
Feedback control. AMP, GMP, UMP, and dNTPs feedback-inhibit their own synthesis. PRPP, an allosteric activator, coordinates flux across pathways.
Key Players / Molecular Components
- PRPP synthetase. Generates activated ribose.
- Glutamine PRPP amidotransferase. Rate-limiting for purine synthesis.
- Carbamoyl phosphate synthetase II, aspartate transcarbamoylase, DHODH. Pyrimidine pathway.
- Thymidylate synthase, dihydrofolate reductase. dTMP production and folate recycling.
- Ribonucleotide reductase. Reduction of NDP to dNDP.
- HGPRT, APRT, TK1, dCK. Salvage enzymes.
Clinical Relevance / Therapeutic Targeting
Nucleotide synthesis inhibitors are a cornerstone of chemotherapy and immunosuppression. Methotrexate inhibits dihydrofolate reductase, limiting folate-dependent reactions including thymidylate synthesis. 5-fluorouracil inhibits thymidylate synthase. Hydroxyurea inhibits ribonucleotide reductase. Azathioprine and 6-mercaptopurine become thioguanine nucleotides, impairing purine synthesis. Leflunomide inhibits DHODH, with immunomodulatory effects; newer DHODH inhibitors (teriflunomide) treat multiple sclerosis. Mycophenolate inhibits IMPDH, depleting GMP in lymphocytes. Lesch-Nyhan syndrome (HGPRT deficiency) causes hyperuricemia, neurologic impairment, and self-mutilation. Adenosine deaminase (ADA) deficiency causes severe combined immunodeficiency.
Peptides That Target This Pathway
- Thymosin alpha-1 — immunomodulatory peptide influencing lymphocyte proliferation (which depends on nucleotide synthesis).
- Thymalin — peptide complex with reported effects on immune cell metabolism.
- Cerebrolysin — neurotrophic preparation with proposed effects on neuronal metabolism.
- Epitalon — pineal peptide studied for effects on cellular aging and proliferation.
- Humanin — mitochondrial-derived peptide with cytoprotective effects.
Related Topics
Related entries
- Amino Acid Catabolism— The pathways that dispose of dietary or mobilized amino acids by separating nitrogen for the urea cycle and channeling carbon skeletons into energy metabolism.
- DNA Damage Response— The DNA damage response is the coordinated network of sensors, signal transducers, and effectors that detects DNA lesions, halts the cell cycle, and orchestrates repair or death.
- Heme Synthesis— The eight-step pathway that builds heme from glycine and succinyl-CoA, essential for hemoglobin, cytochromes, and other hemoproteins.
- Urea Cycle Metabolism— The hepatic cycle that converts ammonia from amino acid breakdown into urea for safe renal excretion.